MorphoSys Appoints New Head of Research Antibody Business

Dieter Feger joins MorphoSys from Leading Diagnostic Supplier Abbott
Diagnostics

MorphoSys AG (FSE: MOR; Prime Standard Segment) announced today the
appointment of a new Head of its AbD Serotec business for research
and diagnostic antibodies. Dieter Feger joins MorphoSys from Abbott
Diagnostics, Illinois, a global leader in in vitro diagnostics. For
the last four years, he held the position of Marketing Director -
Global Marketing, most recently with responsibility for Infectious
Diseases, Abbott Diagnostics' biggest reagent franchise. Prior to
that, he spent 18 years with Abbott in Europe, in a variety of roles
including sales, product management, operational management and
marketing before moving to the US. He replaces Dieter Lingelbach who
has left MorphoSys to pursue new opportunities.

"I am delighted to welcome Dieter Feger to the management team of
MorphoSys. He brings deep experience from his work at Abbott
Diagnostics, one of the industry's leading companies, that will
assist AbD Serotec to seek new growth opportunities and to expand its
footprint in the diagnostics industry," commented Dr Simon Moroney,
Chief Executive Officer of MorphoSys AG. "I would like to thank
Dieter Lingelbach for his invaluable contribution to establishing AbD
Serotec as a leading supplier of research antibodies and wish him
well in the future."

MorphoSys began offering custom antibody services to the research and
diagnostic markets in 2003. Two successful acquisitions of US and
UK-based antibody suppliers with strong catalog and industrial
antibody production businesses have significantly strengthened and
broadened MorphoSys's position in the research antibody market.
Today, MorphoSys's AbD Serotec unit is among the top 20 antibody
suppliers worldwide.

"I'm looking forward to working with the team of AbD Serotec in
Germany, the UK and the US to increase the unit's market share in the
research antibody markets and to seek new opportunities in the
diagnostics industry," commented Dieter Feger, Head of AbD Serotec
and Senior Vice President. "MorphoSys's HuCAL technology is a unique
tool to generate novel research reagents and diagnostics which has
already led to a number of first-of-a-kind products."

MorphoSys will publish its full year 2008 results and financial
guidance for 2009 at its year-end 2008 Results Press Conference and
Analyst Meeting in Frankfurt, Germany on February 26, 2009.
Invitations for the conference in Frankfurt and the webcast will be
sent out in due course.

For further information please contact: Dr. Claudia Gutjahr-Löser,
Head of Corporate Communications & Investor Relations, Tel: +49 (0)
89 / 899 27-122, gutjahr-loeser@morphosys.com or Mario Brkulj, Senior
Manager Corporate Communications & Investor Relations, Tel: +49 (0)
89 / 899 27-454, brkulj@morphosys.com
About MorphoSys:
MorphoSys is a publicly traded biotechnology company focused on the
generation of fully human antibodies as a means to discover and
develop innovative antibody-based drugs against life-threatening
diseases. MorphoSys's goal is to establish HuCAL as the technology of
choice for antibody generation in research, diagnostics and
therapeutic applications. The Company currently has therapeutic and
research alliances with the majority of the world's largest
pharmaceutical companies including Boehringer Ingelheim,
Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these
partnerships, more than 50 therapeutic antibody programs are ongoing
in which MorphoSys participates through exclusive license and
milestones payments as well as royalties on any end products.
Additionally, MorphoSys is active in the antibody research market
through its AbD Serotec business unit. The business unit has
operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K.
(Oxford). For further information please visit
http://www.morphosys.com/

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM® and RapMAT® are registered
trademarks of MorphoSys AG

This communication contains certain forward-looking statements
concerning the MorphoSys group of companies. The forward-looking
statements contained herein represent the judgment of MorphoSys as of
the date of this release and involve risks and uncertainties. Should
actual conditions differ from the Company's assumptions, actual
results and actions may differ from those anticipated. MorphoSys does
not intend to update any of these forward-looking statements as far
as the wording of the relevant press release is concerned.

This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.